457 related articles for article (PubMed ID: 33085861)
21. Benralizumab Completely Depletes Gastrointestinal Tissue Eosinophils and Improves Symptoms in Eosinophilic Gastrointestinal Disease.
Kuang FL; De Melo MS; Makiya M; Kumar S; Brown T; Wetzler L; Ware JM; Khoury P; Collins MH; Quezado M; Pittaluga S; Klion AD
J Allergy Clin Immunol Pract; 2022 Jun; 10(6):1598-1605.e2. PubMed ID: 35283330
[TBL] [Abstract][Full Text] [Related]
22. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease.
Pavord ID; Chanez P; Criner GJ; Kerstjens HAM; Korn S; Lugogo N; Martinot JB; Sagara H; Albers FC; Bradford ES; Harris SS; Mayer B; Rubin DB; Yancey SW; Sciurba FC
N Engl J Med; 2017 Oct; 377(17):1613-1629. PubMed ID: 28893134
[TBL] [Abstract][Full Text] [Related]
23. Severe eosinophilic asthma treated with mepolizumab stratified by baseline eosinophil thresholds: a secondary analysis of the DREAM and MENSA studies.
Ortega HG; Yancey SW; Mayer B; Gunsoy NB; Keene ON; Bleecker ER; Brightling CE; Pavord ID
Lancet Respir Med; 2016 Jul; 4(7):549-556. PubMed ID: 27177493
[TBL] [Abstract][Full Text] [Related]
24. Quantification of Mucosal Eosinophils for the Histopathologic Diagnosis of Eosinophilic Gastritis and Duodenitis: A Primer for Practicing Pathologists.
Turner KO; Collins MH; Walker MM; Genta RM
Am J Surg Pathol; 2022 Apr; 46(4):557-566. PubMed ID: 34913877
[TBL] [Abstract][Full Text] [Related]
25. Clinical characteristics, treatment outcomes, and resource utilization in children and adults with eosinophilic gastroenteritis.
Reed C; Woosley JT; Dellon ES
Dig Liver Dis; 2015 Mar; 47(3):197-201. PubMed ID: 25547198
[TBL] [Abstract][Full Text] [Related]
26. Dupilumab Can Induce Remission of Eosinophilic Gastritis and Duodenitis: A Retrospective Case Series.
Sia T; Bacchus L; Tanaka R; Khuda R; Mallik S; Leung J
Clin Transl Gastroenterol; 2024 Jan; 15(1):e00646. PubMed ID: 37753954
[TBL] [Abstract][Full Text] [Related]
27. Association between defective spleen function and primary eosinophilic gastrointestinal disorders.
Di Sabatino A; Aronico N; Giuffrida P; Cococcia S; Lenti MV; Vanoli A; Guerci M; Di Stefano M; Corazza GR
J Allergy Clin Immunol Pract; 2018; 6(3):1056-1058.e1. PubMed ID: 29128338
[No Abstract] [Full Text] [Related]
28. Clinical and histologic remission achieved with upadacitinib in a patient with refractory eosinophilic gastritis and duodenitis.
Fu J; Sia T; Solecki R; Mallik S; Khuda R; Headen M; Bacchus L; Zheng M; Telukunta T; Shami S; Liu S; Sureshbabu S; Love K; Roby A; McDonald P; Jiang Y; Narayanan DH; Cunningham E; Matmatte AS; Tan PE; Leung J
J Allergy Clin Immunol Pract; 2024 Jun; 12(6):1649-1651. PubMed ID: 38423296
[No Abstract] [Full Text] [Related]
29. Benralizumab, an anti-interleukin-5 receptor α monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial.
FitzGerald JM; Bleecker ER; Nair P; Korn S; Ohta K; Lommatzsch M; Ferguson GT; Busse WW; Barker P; Sproule S; Gilmartin G; Werkström V; Aurivillius M; Goldman M;
Lancet; 2016 Oct; 388(10056):2128-2141. PubMed ID: 27609406
[TBL] [Abstract][Full Text] [Related]
30. Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
Montalban X; Hauser SL; Kappos L; Arnold DL; Bar-Or A; Comi G; de Seze J; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Rammohan KW; Selmaj K; Traboulsee A; Sauter A; Masterman D; Fontoura P; Belachew S; Garren H; Mairon N; Chin P; Wolinsky JS;
N Engl J Med; 2017 Jan; 376(3):209-220. PubMed ID: 28002688
[TBL] [Abstract][Full Text] [Related]
31. Anti-interleukin-5 antibody treatment (mepolizumab) in active eosinophilic oesophagitis: a randomised, placebo-controlled, double-blind trial.
Straumann A; Conus S; Grzonka P; Kita H; Kephart G; Bussmann C; Beglinger C; Smith DA; Patel J; Byrne M; Simon HU
Gut; 2010 Jan; 59(1):21-30. PubMed ID: 19828470
[TBL] [Abstract][Full Text] [Related]
32. Phase 3 Study of Reslizumab in Patients With Poorly Controlled Asthma: Effects Across a Broad Range of Eosinophil Counts.
Corren J; Weinstein S; Janka L; Zangrilli J; Garin M
Chest; 2016 Oct; 150(4):799-810. PubMed ID: 27018175
[TBL] [Abstract][Full Text] [Related]
33. Effect of tralokinumab, an interleukin-13 neutralising monoclonal antibody, on eosinophilic airway inflammation in uncontrolled moderate-to-severe asthma (MESOS): a multicentre, double-blind, randomised, placebo-controlled phase 2 trial.
Russell RJ; Chachi L; FitzGerald JM; Backer V; Olivenstein R; Titlestad IL; Ulrik CS; Harrison T; Singh D; Chaudhuri R; Leaker B; McGarvey L; Siddiqui S; Wang M; Braddock M; Nordenmark LH; Cohen D; Parikh H; Colice G; Brightling CE;
Lancet Respir Med; 2018 Jul; 6(7):499-510. PubMed ID: 29793857
[TBL] [Abstract][Full Text] [Related]
34. Safety and efficacy of AMG 714 in adults with coeliac disease exposed to gluten challenge: a phase 2a, randomised, double-blind, placebo-controlled study.
Lähdeaho ML; Scheinin M; Vuotikka P; Taavela J; Popp A; Laukkarinen J; Koffert J; Koivurova OP; Pesu M; Kivelä L; Lovró Z; Keisala J; Isola J; Parnes JR; Leon F; Mäki M
Lancet Gastroenterol Hepatol; 2019 Dec; 4(12):948-959. PubMed ID: 31494096
[TBL] [Abstract][Full Text] [Related]
35. Quantification of the duodenal eosinophil content in adults: a necessary step for an evidence-based diagnosis of duodenal eosinophilia.
Genta RM; Sonnenberg A; Turner K
Aliment Pharmacol Ther; 2018 Apr; 47(8):1143-1150. PubMed ID: 29488232
[TBL] [Abstract][Full Text] [Related]
36. Eosinophilic gastroenteritis: clinical manifestations and morphological characteristics, a retrospective study of 42 patients.
Zhang L; Duan L; Ding S; Lu J; Jin Z; Cui R; McNutt M; Wang A
Scand J Gastroenterol; 2011 Sep; 46(9):1074-80. PubMed ID: 21623674
[TBL] [Abstract][Full Text] [Related]
37. Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies.
FitzGerald JM; Bleecker ER; Menzies-Gow A; Zangrilli JG; Hirsch I; Metcalfe P; Newbold P; Goldman M
Lancet Respir Med; 2018 Jan; 6(1):51-64. PubMed ID: 28919200
[TBL] [Abstract][Full Text] [Related]
38. Immune-related adverse events in a patient with eosinophilic enteritis treated with immune checkpoint inhibitors (anti-PD-1).
Cybulska-Stopa B; Kamińska-Winciorek G; Dyduch G
Melanoma Res; 2020 Dec; 30(6):619-624. PubMed ID: 32809991
[TBL] [Abstract][Full Text] [Related]
39. Reslizumab in children and adolescents with eosinophilic esophagitis: results of a double-blind, randomized, placebo-controlled trial.
Spergel JM; Rothenberg ME; Collins MH; Furuta GT; Markowitz JE; Fuchs G; O'Gorman MA; Abonia JP; Young J; Henkel T; Wilkins HJ; Liacouras CA
J Allergy Clin Immunol; 2012 Feb; 129(2):456-63, 463.e1-3. PubMed ID: 22206777
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
